• 1
    Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B. September 14-16, 2002. J Hepatol 2003; 39( Suppl 1): S3-S2.
  • 2
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673-2681.
  • 3
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-1661.
  • 4
    Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263.
  • 5
    Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68.
  • 6
    Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172-180.
  • 7
    Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. HEPATOLOGY 2001; 33: 1527-1532.
  • 8
    Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-696.
  • 9
    Zoulim F. Hepatitis B virus resistance to antivirals: clinical implications and management. J Hepatol 2003; 39: S133-S138.
  • 10
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-807.
  • 11
    Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816.
  • 12
    Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. HEPATOLOGY 2000; 32: 129-134.
  • 13
    Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. HEPATOLOGY 1998; 28: 1669-1673.
  • 14
    Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. HEPATOLOGY 2004; 39: 857-861.
  • 15
    Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-297.
  • 16
    Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 1085-1089.
  • 17
    Hadziyannis S, Tassopoulos NC, Chang TT, Heathcote J, Kitis G, Rizzetto M, et al. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy [Abstract]. HEPATOLOGY 2005; 42: LBA14.
  • 18
    Locarnini S, Qi X, Arterburn S, Snow A, Brosgart CL, Currie G, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) [Abstract]. J Hepatol 2005; 42: A36.
  • 19
    Ono Y, Onda H, Sasada R, Igarashi K, Sugino Y, Nishioka K. The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw. Nucleic Acids Res 1983; 11: 1747-1757.
  • 20
    Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001; 80: 63-71.
  • 21
    Hong SP, Kim NK, Hwang SG, Chung HJ, Kim S, Han JH, et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 2004; 40: 837-844.
  • 22
    Westland CE, Yang H, Delaney IVWE, Gibbs CS, Miller MD, Wulfsohn M, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. HEPATOLOGY 2003; 38: 96-103.
  • 23
    Fung SK, Andreone P, Han SH, Reddy KR, Regev A, Keeffe EB, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005; 43: 937-943.
  • 24
    Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. HEPATOLOGY 2003; 38: 1419-1427.
  • 25
    Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero JA, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283-290.
  • 26
    Colonno R, Rose R, Levine S, Baldick J, Pokornowski K, Plym M, et al. Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients [Abstract]. HEPATOLOGY 2005; 42( Suppl): 962A.
  • 27
    Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouee-Durantel S, Villeneuve JP, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. HEPATOLOGY 2005; 41: 1391-1398.
  • 28
    Chin R, Locarnini S. Treatment of chronic hepatitis B: current challenges and future directions. Rev Med Virol 2003; 13: 255-272.
  • 29
    Yang H, Westland CE, Delaney IVWE, Heathcote EJ, Ho V, Fry J, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. HEPATOLOGY 2002; 36: 464-473.
  • 30
    Locarnini S, Shaw T, Sozzi T, Edwards R, Currie G, Brosgart C, et al. HBV mutants associated with clinical resistance to adefovir dipivoxil display only small decreases in antiviral sensitivity in vitro [Abstract]. HEPATOLOGY 2004; 40( Suppl): A383.
  • 31
    Yang H, Qi X, Das K, Arnold E, Westland CE, Delaney WE, et al. In vitro characterization and molecular modeling analysis of a novel adefovir resistance mutation rtN236T in the HBV polymerase [Abstract]. J Hepatol 2004; 40: A383.
  • 32
    Kim HS, Han KH, Ahn SH, Kim EO, Chang HY, Moon MS, et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther 2005; 10: 441-449.
  • 33
    Kim YJ, Kim SO, Chung HJ, Jee MS, Kim BG, Kim KM, et al. Population genotyping of hepatitis C virus by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of short DNA fragments. Clin Chem 2005; 51: 1123-1131.